Atyr Pharma, Inc. · NASDAQ:ATYR
Atyr Pharma — Investor Presentation (May 2020)
31 slides from Atyr Pharma's investor presentation, May 18, 2020
Slide 1: A New Path to Medicine
A New Path to Medicine MAY 2020 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “should,” “expect,”
Slide 3: aTyr: A New Path to Medicine
aTyr: A New Path to Medicine Mission Develop a new class of medicine based on proprietary biology platform Phase 2 clinical program: ATYR1923 Potential first-in-class immunomodulator for inflammatory lung diseases Phase 1b/2a study in pulmonary sarcoidosis, a major form of interstitial lung disease
Slide 4: aTyr Development Pipeline
aTyr Development Pipeline CTD-ILD = connective tissue disease-related ILD; CHP = chronic hypersensitivity pneumonitis Kyorin partnership for ILD in Japan CSL partnership for up to 4 tRNA synthetases PROGRAM DISEASES DISCOVERY PRECLINCAL PHASE 1 PHASE 2 PHASE 3 Partners ATYR1923 Pulmonary Sarcoidosis
Slide 5: tRNA Synthetases May Have Novel Functions Extracellularly
tRNA Synthetases May Have Novel Functions Extracellularly
Slide 6: ATYR1923: A Novel Immunomodulator for Inflammatory Lung Disease
ATYR1923 A Novel Immunomodulator for Inflammatory Lung Disease
Slide 7: A Novel Mechanism to Treat Inflammation
A Novel Mechanism to Treat Inflammation Representative histology showing immune cell infiltrate in a rat model of bleomycin induced lung fibrosis presented at the American Thoracic Society annual meeting 2018. Injured lung ATYR1923 treated Healthy lung
Slide 8: ATYR1923: Potential First-in-Class Therapy for Inflammatory Lung Disease
ATYR1923: Potential First-in-Class Therapy for Inflammatory Lung Disease Fc fusion protein therapeutic derived from aTyr’s proprietary protein library Binds selectively to NRP2, a cell surface receptor upregulated in inflamed lung tissue Downregulates inflammatory and pro-fibrotic cytokine and chemo
Slide 9: ATYR1923 Mechanism of Action in Inflammatory Lung Disease
ATYR1923 Mechanism of Action in Inflammatory Lung Disease
Slide 10: First Identified Mechanism: Inhibition of T Cell Activation
First Identified Mechanism: Inhibition of T Cell Activation Modified from in vitro data presented at AAI 2018; * = p < 0.05; N15 = negative control for ATYR1923 Human naïve T cells Stimulated with anti-CD3/CD28 Also inhibits release of other cytokines: IFNγ, IL-17, IL-5, IL-13, IL-21, IL-10, TNFα CD
Slide 11: Demonstrated Effect in Animal Lung Injury Models
Demonstrated Effect in Animal Lung Injury Models Data available at https://www.atyrpharma.com/our-science/publications/ Fibrosis Inflammation Bleomycin-Induced Lung Fibrosis (IPF) P. acnes (Sarcoidosis) Sclerodermatous GvHD (SSc-ILD) SKG mice (RA-ILD) S. Rectivirgula (CHP) ↓ inflammation / fibrosis
Slide 12: ATYR1923 Interstitial Lung Disease
ATYR1923 Interstitial Lung Disease
Slide 13: ILDs Share Common Immune Pathology Leading to Fibrosis
ILDs Share Common Immune Pathology Leading to Fibrosis Slide adapted from Dr. Steven Nathan, Medical Director, Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital, Falls Church, VA Fibrosis Pulmonary Sarcoidosis Connective Tissue Disease related – ILD (CTD-ILD) Chronic Hypersensit
Slide 14: Market Opportunity in Inflammatory Interstitial Lung Disease
Market Opportunity in Inflammatory Interstitial Lung Disease Lederer, Martinez. NEJM 2018 All ILDs individually have potential for orphan status aTyr estimates for ATYR1923 in Pulmonary Sarcoidosis, CHP, CTD-ILD; excludes IPF >200 types of ILD: 4 major types comprise 80% of patients Limited standard
Slide 15: First ATYR1923 Indication: Pulmonary Sarcoidosis
First ATYR1923 Indication: Pulmonary Sarcoidosis Inflammatory disease of unknown etiology characterized by the formation of granulomas (clumps of immune cells) T cell driven: CD4+ (Th1 / Th17) Pulmonary sarcoidosis occurs in ~90% of all sarcoidosis patients Treatment options are limited with associa
Slide 16: Phase 1b/2a Study in Pulmonary Sarcoidosis Ongoing
Phase 1b/2a Study in Pulmonary Sarcoidosis Ongoing Design Randomized (2:1), double-blind, placebo-controlled, multiple ascending dose Forced steroid taper to 5 mg by week 8; taper to 0 mg possible at week 16 in responders Population 36 histologically confirmed pulmonary sarcoidosis patients ≥10 mg s
Slide 17: Phase 1b/2a Pulmonary Sarcoidosis Study Schema
Phase 1b/2a Pulmonary Sarcoidosis Study Schema (1) subtherapeutic dose 0 4 8 12 16 20 24 24-week Study Period Week Each Cohort: Dose Escalation Review after 6 patients have received ≥3 doses of study drug ATYR1923 Placebo 5 mg OCS(1) Steroid taper every 2 weeks Primary endpoint 5.0 mg/kg 3.0 mg/kg C
Slide 18: ATYR1923 Japan Collaboration
ATYR1923 Japan Collaboration Kyorin Overview Founded: 1923 Focus: Respiratory, ENT, Urology 1600 employees: incl. 350 in R&D; 750 sales reps covering top respiratory centers in Japan Sales: ~$1b USD Market cap: $1.1b USD (4569:JP TSE) Key Terms Scope: ATYR1923; Japan; ILD Upfront payment: $8m Develo
Slide 19: ATYR1923 COVID-19 Related Severe Respiratory Complications
ATYR1923 COVID-19 Related Severe Respiratory Complications
Slide 20: ATYR1923 for COVID-19 Related Severe Respiratory Complications
ATYR1923 for COVID-19 Related Severe Respiratory Complications A subset of COVID-19 patients progress to experience significant inflammatory infiltration of the lungs Severely ill patients have significant increases of several pro-inflammatory cytokines: IL-2, -7, -6 and 10, G-CSF, MCP1, MIP1A and T
Slide 21: ATYR1923 Phase 2 Study in COVID-19 Related Severe Respiratory Complications
ATYR1923 Phase 2 Study in COVID-19 Related Severe Respiratory Complications Objective Evaluate safety and preliminary efficacy of ATYR1923 in subjects with COVID-19-related severe respiratory complications not requiring mechanical ventilation Design Randomized, double-blind, placebo controlled, sing
Slide 22: NRP2 Antibodies Regulating Diverse Disease Pathways
NRP2 Antibodies Regulating Diverse Disease Pathways
Slide 23: NRP2: A Novel Therapeutic Target
NRP2: A Novel Therapeutic Target NRP2 is a potentially novel target for cancer and inflammatory disorders Acts as a co-receptor for VEGF-C, class 3 Semaphorins and CCL21 NRP2 expression is upregulated on tumors and immune cells during inflammation NRP2 expression is linked to worse outcomes in many
Slide 24: NRP2 is a Compelling Target for Cancer and Inflammation
NRP2 is a Compelling Target for Cancer and Inflammation INFLAMMATION LYMPH- ANGIOGENESIS CANCER SEMA3F SEMA3F VEGF-C VEGF-C CCL21 Expressed on multiple immune cell types Expression upregulated in inflammatory conditions Overexpressed in a variety of cancers Tumor expression linked to worse outcomes
Slide 25: aTyr is Developing Human NRP2 Blocking Antibodies
aTyr is Developing Human NRP2 Blocking Antibodies (1) Distinct from ATYR1923 interaction with NRP2 SEMA3F VEGF-C Dimerization domain a1 a2 b1 b2 c VEGF-C Blocker a-NRP2-10 CCL21 Blocker(s) Under evaluation SEMA3F Blocker a-NRP2-14 aTyr lead antibodies(1)
Slide 26: tRNA Synthetases A Potential New Therapeutic Protein Class
tRNA Synthetases A Potential New Therapeutic Protein Class
Slide 27: tRNA Synthetases: A Potential New Therapeutic Protein Class
tRNA Synthetases: A Potential New Therapeutic Protein Class aTyr owns IP covering proteins derived from all 20 tRNA synthetase gene families Lead program ATYR1923 is based on a naturally occurring splice variant of one of these families, histidyl-tRNA synthetase (HARS) tRNA synthetases are secreted
Slide 28: A New Path to Medicine
allyr A New Path to Medicine
Slide 29: aTyr: A New Path to Medicine
aTyr: A New Path to Medicine Platform of proprietary new biology Phase 2 clinical program: ATYR1923 Novel MOA for inflammatory lung disease Demonstrated effect in multiple animal lung injury models Phase 1 in healthy volunteers completed Phase 1b/2a clinical study in pulmonary sarcoidosis enrolling
Slide 30: Upcoming Catalysts
Upcoming Catalysts ATYR1923 Phase 1b/2a results in pulmonary sarcoidosis patients(1) Initiation of Phase 1 in Japan Phase 2 results in COVID-19 patients by end of year(2) Potential expansion into Phase 2 studies for second ILD indication NRP2 Antibodies Selection of first NRP2 antibody IND candidate
Slide 31: Thank You
alyr Thank You